Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Leqembi targets aggregated soluble amyloid beta to slow early Alzheimer’s progression; it does not restore all lost cognition.
Read source section ↗Mechanism of action
Promotes clearance of aggregated amyloid beta; amyloid-related imaging abnormalities (ARIA) require surveillance.
Read source section ↗Japanese indications & eligibility
For mild cognitive impairment or mild dementia due to Alzheimer’s, with confirmed amyloid pathology and eligibility checks. This record covers IV products.
Read source section ↗Administration & dose differences
The Japanese IV schedule is 10 mg/kg every two weeks, infused over approximately one hour.
Read source section ↗Adverse effects & key risks
Key risks are ARIA-E, ARIA-H and infusion reactions. ARIA may be symptomatic or found only on imaging.
Read source section ↗Contraindications & special populations
Contraindications include severe hypersensitivity and specified baseline edema or hemorrhagic MRI findings.
Read source section ↗Drug interactions
Anticoagulants, antiplatelets and thrombolytics require careful hemorrhage-risk assessment.
Read source section ↗Assessment & monitoring
Baseline and scheduled MRI, symptom-triggered imaging and cognitive/function follow-up are required.
Read source section ↗Storage & handling
Refrigerate at 2–8°C; do not freeze or shake. Protect from light. The photo is the 500 mg IV vial.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-09.
- Manufacturer information ↗medical.eisai.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
